Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Replicel Life Sciences Inc (OP: REPCF ) N/A UNCHANGED Last Price Updated: 11:20 AM EDT, Mar 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0428 Today's Range N/A - N/A 52wk Range 0.0257 - 0.0930 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News RepliCel Provides Corporate Update November 28, 2022 Via ACCESSWIRE RepliCel Announces Material Patent Milestones in Key Markets August 04, 2022 Via ACCESSWIRE Performance More News Read More DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections August 02, 2022 Via ACCESSWIRE RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Material Patent Milestones January 10, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Closed Final Tranche of Strategic Investment Commitment December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Terminates License Agreement with Shiseido December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 09, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line October 28, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Dermal Injector Update October 27, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Economy Exposures Economy RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies July 07, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Adds Independent Director June 15, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Artificial Intelligence Exposures Artificial Intelligence RepliCel Launches Testing of Dermal Injector Units May 25, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor May 17, 2021 From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.